Aarti Pharmalabs

    AARTIPHARM
    Pharma
    ₹1,013.40
    Price as of 18 Nov 2026, 9:58 pm IST

    Market cap ₹9,189 Cr

    P/E
    35.82
    Day range
    ₹992.45 – ₹1,028.95
    52-week range
    ₹585.00 – ₹1,047.25
    Volume
    5.77 L
    Open
    ₹1,007.00
    Prev close
    ₹1,015.90

    Latest results · Q2 FY27(consolidated)Revenue ₹610 Cr+45.9%Profit ₹71 Cr+156.0%Margin 11.7%YoY vs the same quarter last year

    3 red flags to read up on

    • high

      Promoters selling in the market

      Promoter group sold a net ₹222 Cr on the open market in 90 days · 22 Sept 2026

    • medium

      Promoter pledge went up

      11.98% of promoter shares pledged, up from 11.08% · 30 Sept 2026

    • medium

      Promoter holding falling

      39.66%, down 3.22 pts since 2025-09-30 · 30 Sept 2026

    From NSE and BSE filings. A flag is a reason to read the filing, not a rating.

    Research profile

    Composite 50 / 100

    Factor percentiles

    Value39
    Quality44
    Momentum87
    Low volatility32

    Derived metrics

    Earn. yield
    2.8%
    Graham no.
    ₹403.92
    vs Graham
    -60.1%
    ROE ÷ P/B
    2.1%
    12-1 mom.
    +14.0%
    Return / vol
    0.71
    Magic Formula
    #461
    Piotroski
    4/6
    FCF yield
    -2.0%
    PEG
    0.23

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 68 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.49 L Cr40.955.0314.8%21.0%29.0%0.04+11.9%
    Divi's LaboratoriesDIVISLAB₹2.93 L Cr87.1916.8816.2%22.0%43.0%0.00+35.4%
    Torrent PharmaTORNTPHARM₹1.75 L Cr77.889.6726.8%15.0%33.0%0.77+50.8%
    Apollo HospitalsAPOLLOHOSP₹1.27 L Cr56.4011.5522.6%17.0%16.0%0.77+23.0%
    Laurus LabsLAURUSLABS₹1.25 L Cr93.7219.8218.2%18.0%34.0%0.43+33.5%
    Zydus LifesciencesZYDUSLIFE₹1.20 L Cr28.724.3220.1%21.0%24.0%0.50+29.2%
    Dr. Reddy's LabsDRREDDY₹1.17 L Cr41.632.9711.6%13.0%20.0%0.19-1.5%
    Aarti PharmalabsAARTIPHARM₹9,189 Cr35.824.018.5%11.0%22.0%0.40+45.9%
    Sector median₹24,603 Cr43.685.4615.1%17.0%24.0%0.17+22.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 1m ago

    Headlines about Aarti Pharmalabs from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.

    Key metrics

    P/E (TTM)
    35.3
    EPS (TTM)
    ₹26.81
    Price / Book
    4.07
    ROE (FY26)
    8.5%
    ROCE (latest year)
    11%
    Dividend yield
    0.35%

    Moving averages (NSE)

    20-day
    ₹917.31
    Price above
    50-day
    ₹896.6
    Price above
    200-day
    ₹759.1
    Price above

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    -2.2%
    Profit 3Y CAGR
    -3.2%
    Revenue YoY (Sep 2026)
    +45.9%
    Profit YoY (Sep 2026)
    +153.6%
    Operating margin
    22.0%
    Net margin
    11.6%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    0 Cr200 Cr400 Cr600 Cr800 Cr
    • Revenue
    • Net profit

    Operating margin

    Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Sep 20260%15%30%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '24Mar '25Jun '25Sept '25Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • Public
    • Promoter
    • DII
    • FII
    • Government

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2020 (S)Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-600 Cr-400 Cr-200 Cr0 Cr200 Cr400 Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY21FY22FY23FY24FY25FY260%5%10%15%20%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    0 Cr1K Cr2K Cr3K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2020 (S)Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 20260x0.5x1x

    Dividends per share

    ₹ by fiscal year of the ex-date; the latest year runs to date.

    FY25FY26FY27₹0₹1₹2₹3₹4

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
    Sales449506555458538564386418432583536610
    YoY Sales growth-5—————-30-9-20———
    Expenses353388459364409418293344330470400475
    Operating Profit9611896941291469374102113136135
    OPM %21%23%17%20%24%26%24%18%24%19%25%22%
    Other Income12245-22021485
    Interest455610771113171315
    Depreciation191920212323232529283031
    Profit before tax749674721011156539638210195
    Tax %29%32%25%24%26%23%24%28%24%25%25%25%
    Net Profit536555557488502848617671
    EPS in Rs₹5.82₹7.20₹6.12₹6.03₹8.16₹9.75₹5.46₹3.08₹5.29₹6.74₹8.40₹7.88

    From company filings, updated 19 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days117

    +2 days since Mar 2022

    Inventory Days280

    +8 days since Mar 2022

    Days Payable146

    +23 days since Mar 2022

    Cash Conversion Cycle251

    -13 days since Mar 2022

    Working Capital Days90

    -21 days since Mar 2022

    Strengths, risks & growth

    Incorporated in 2019, Aarti Pharmalabs Ltd is a manufacturer of Pharmaceuticals and Nutraceuticals [1]

    Strengths

    • Company is expected to give good quarter

    Risks

    • Stock is trading at 4.08 times its book value
    • Promoter holding has decreased over last quarter: -3.20%
    • Company has a low return on equity of 11.9% over last 3 years.

    Compounded Sales Growth

    10 Years
    —
    5 Years
    —
    3 Years
    -2%
    TTM
    +13%

    Compounded Profit Growth

    10 Years
    —
    5 Years
    —
    3 Years
    -3%
    TTM
    +9%

    Stock Price CAGR

    10 Years
    —
    5 Years
    —
    3 Years
    +36%
    1 Year
    +43%

    Return on Equity

    10 Years
    —
    5 Years
    +13%
    3 Years
    +12%
    Last Year
    +9%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter43.10%43.08%42.86%39.66%-3.20 pp
    FII7.69%8.39%8.17%8.16%-0.01 pp
    DII7.66%7.40%7.22%8.40%+1.18 pp
    Government0.01%0.01%0.01%0.01%0.00 pp
    Public41.54%41.10%41.74%43.78%+2.04 pp

    Filed with NSE for Sept 2026: promoters 39.66%, public 60.34%

    Analysts & fund holdings

    0%
    0% recommend buy
    1 analysts cover the stock
    Valuation vs Life Sciences Tools & Services
    P/E35.8 vs 45.2
    Sector P/B6.05
    Beta0.84

    Who holds the shares, quarter by quarter

    Mutual funds 0.60% (-0.19 pp)
    Jun 25
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    Sept 26
    • Promoters39.7%
    • Foreign institutions8.2%
    • Mutual funds0.6%
    • Insurance4.8%
    • Other domestic institutions3.0%
    • Retail25.4%
    • Others18.4%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    Motilal Oswal Nifty Microcap 250 Index Fund0.15%0.55%+0.18 pp
    UTI Healthcare Fund0.15%0.91%+0.18 pp
    Union Active Momentum Fund0.11%1.82%+1.82 pp
    WOC Pharma and Healthcare Fund0.11%1.06%+0.22 pp
    Unifi Flexi Cap Fund0.09%3.11%+1.86 pp

    Scorecard

    Performance
    Low
    Valuation
    High
    Growth
    Low
    Profitability
    High
    Entry point
    Avg
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.

    Risk & trend

    From 292 daily sessions to 18 Nov 2026.

    Computed

    Risk

    Volatility (1Y)
    45.5%
    Downside volatility
    41.2%
    Worst 5% of days
    4.3%
    Average of that tail
    5.7%
    Max drawdown (1Y)
    37.0%
    Below its peak
    0.2%

    Against the market

    Beta vs Nifty 50
    1.12
    Correlation
    0.33
    Relative strength (3M)
    +13.7%
    ATR (14)
    4.5%

    Return

    Return 1M
    +16.0%
    Return 3M
    +17.6%
    Return 6M
    +44.5%
    Return 1Y
    +32.3%
    vs 200-day average
    +33.5%

    Momentum

    RSI (14)
    66.0
    MACD histogram
    11.61
    Stochastic %K
    82.4
    ADX (14)
    32.3
    +DI / −DI
    30.2 / 10.3
    Money flow index
    72.3

    Participation

    Delivery (20d avg)
    42.8%
    vs its 60-day baseline
    -0.2 pts
    Volume vs 20-day
    -0.2σ
    Close vs day's VWAP
    +0.3%
    52-week position
    99 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 30 Sept 2026.

    Computed

    Piotroski F-Score

    4 of 6 tested

    • Return on assets positive — passed
    • Operating cash flow positive — not testableno cash flow statement for this period
    • Return on assets improving — passed
    • Cash flow exceeds profit — not testableneeds cash flow and profit against assets
    • Debt to assets falling — failed
    • Current ratio improving — failed
    • No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
    • Operating margin improving — passed
    • Asset turnover improving — passed
    Free cash flow
    -₹186 Cr
    FCF yield
    -2.0%
    Cash conversion
    1.40
    Accruals ratio
    -0.022
    Net debt
    ₹893 Cr
    Net debt / equity
    0.40
    EV / sales
    4.67
    PEG
    0.23
    Capex intensity
    24.6%
    Revenue CAGR
    45.9%
    Profit CAGR
    156.0%

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Insider trades

    Last 12 months, market trades
    Net selling ₹228 Cr
    2 buys · ₹4.5 Cr
    17 sells · ₹232 Cr
    Latest insider trades disclosed to NSE
    PersonTypeSharesValueDisclosed
    ARTI RAJENDRA GOGRI
    Promoter Group · Market Sale
    Sell1,33,564₹10.9 Cr25 Sept 2026
    Relacion Trusteeship Services Private Limited
    Promoter · Market Sale
    Sell3,80,000₹31.1 Cr25 Sept 2026
    Gloire Trusteeship Services Private Limited
    Promoter Group · Market Sale
    Sell3,97,500₹32.5 Cr25 Sept 2026
    RAJENDRA VALLABHAJI GOGRI
    Promoter · Market Sale
    Sell3,88,725₹31.8 Cr25 Sept 2026
    Gloire Trusteeship Services Private Limited
    Promoter Group · Market Sale
    Sell6,24,500₹51.1 Cr22 Sept 2026
    Relacion Trusteeship Services Private Limited
    Promoter Group · Market Sale
    Sell6,27,500₹51.4 Cr22 Sept 2026
    Safechem Enterprises Private Limited
    Promoter Group · Market Sale
    Sell59,400₹5.2 Cr9 Sept 2026
    Relacion Trusteeship Services Private Limited
    Promoter Group · Market Sale
    Sell60,000₹5.2 Cr9 Sept 2026
    Safechem Enterprises Private Limited
    Promoter Group · Market Sale
    Sell30,000₹2.6 Cr7 Sept 2026
    Safechem Enterprises Private Limited
    Promoter Group · Market Sale
    Sell600₹5.1 L31 Aug 2026
    Safechem Enterprises Private Limited
    Promoter Group · Market Sale
    Sell15,000₹1.3 Cr19 Aug 2026
    Safechem Enterprises Private Limited
    Promoter Group · Market Sale
    Sell23,482₹2.1 Cr18 Aug 2026

    Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.

    Corporate actions

    • dividend
      ₹2.00

      Dividend - Rs 2 Per Share

      15 Sept 2026
      ex-date
    • dividend
      ₹1.50

      Interim Dividend - Rs 1.50 Per Share

      16 Feb 2026
      ex-date
    • dividend
      ₹2.50

      Dividend - Rs 2.50 Per Share

      15 Sept 2025
      ex-date
    • dividend
      ₹2.50

      Interim Dividend - Rs 2.50 Per Share

      14 Feb 2025
      ex-date
    • dividend
      Not available — not reported in this filing

      Dividend - Re 1 Per Share

      31 Jul 2024
      ex-date
    • dividend
      ₹2.00

      Interim Dividend - Rs 2 Per Share

      16 Feb 2024
      ex-date

    Company announcements

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    This is to inform you that the Earnings Conference Call for investors and analysts has been scheduled for Thursday, October 28, 2026, at 3:30 p.m. (IST) to discuss the Company's Q2-FY27 ....

    Board MeetingPrice-sensitive
    Board Meeting Intimation for Approval Of Unaudited Standalone And Consolidated Financial Results For The Second Quarter And Half Year Ended September 30, 2026

    Aarti Pharmalabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/10/2026 ,inter alia, to consider and approve Unaudited Standalone And Consolidated ....

    Company Update
    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018, for the quarter ended September 30, 2026.

    Company Update
    Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

    Please find enclosed

    Company Update
    Intimation Under Regulation 30 Of SEBI Listing Regulations

    Please find enclosed

    Insider Trading / SAST
    Closure of Trading Window
    Company Update
    Updates On Change In Directorate

    Please find enclosed

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    Scrutinizers Report and Voting Result of 7th Annual General Meeting

    Insider Trading / SAST
    Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

    The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Gloire Trusteeship Services Pvt Ltd & Others

    Company Update
    Announcement under Regulation 30 (LODR)-Investor Presentation

    Investor Presentation made at the 7th Annual General Meeting

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Outcome of AGM

    Proceedings of the 7th Annual General Meeting

    Company Update
    Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

    Please find enclosed

    Company Update
    Announcement under Regulation 30 (LODR)-Change in Management

    Please find enclosed

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Please find enclosed

    Others
    Business Responsibility and Sustainability Reporting (BRSR)

    Please find enclosed BRSR for FY 2025-26

    Filed with BSE (scrip 543748); the last 45 days. Documents open at bseindia.com.

    Documents

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 29 Oct 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Aarti Pharmalabs: common questions

    Answered from the figures on this page.

    Aarti Pharmalabs last traded at ₹1,013.40 (NSE, as of 18 Nov 2026). The last session moved it down 0.25%.

    Aarti Pharmalabs is valued at about ₹9,189 crore (NSE, as of 18 Nov 2026).

    Aarti Pharmalabs trades at a price-to-earnings ratio of 35.82 (NSE, as of 18 Nov 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Aarti Pharmalabs has traded between ₹585.00 and ₹1,047.25 over the past 52 weeks, to 18 Nov 2026. It is currently 93% of the way up that range.

    Aarti Pharmalabs (AARTIPHARM) is classified under Pharma on this site's screener.